Epizyme Expands Series B Round to $40 Million
Epizyme Inc., a Cambridge, Mass.-based biopharma company focused on the application of epigenetics, has raised $8 million in new Series B funding from Newe Enterprise Associates. This brings the round total to $40 million, including an earlier close led by Bay City Capital. The initial tranche also included Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers. The company has now raised $54 million in total VC funding.
8 December 2009•3 mins read
